Annexin A3 as a Prognostic Biomarker for Breast Cancer: A Retrospective Study

To validate the correlation between ANXA3 expression and prognosis in breast cancer, a retrospective study encompassing 309 breast cancer patients was performed. The expression of ANXA3 was determined by the immunohistochemical examination of tissue sections by the Max Vision™ method. The ANXA3 leve...

Full description

Saved in:
Bibliographic Details
Published in:BioMed research international 2017-01, Vol.2017 (2017), p.1-7
Main Authors: Zhang, Lina, Tang, Tiantian, Yang, Li, Li, Yong, Zhou, Tao, Shi, Jiajie
Format: Article
Language:English
Subjects:
Adult
Aged
Analysis
Annexin A3 - biosynthesis
Annexins
Biological markers
Biomarkers, Tumor - biosynthesis
Breast cancer
Breast Neoplasms - metabolism
Breast Neoplasms - mortality
Breast Neoplasms - pathology
Disease-Free Survival
Female
Follow-Up Studies
Humans
Immunoglobulins
Immunohistochemistry
Lymphatic Metastasis
Medical prognosis
Metastasis
Middle Aged
Neoplasm Proteins - biosynthesis
Prognosis
Retrospective Studies
Signal transduction
Survival Rate
Tumorigenesis
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:To validate the correlation between ANXA3 expression and prognosis in breast cancer, a retrospective study encompassing 309 breast cancer patients was performed. The expression of ANXA3 was determined by the immunohistochemical examination of tissue sections by the Max Vision™ method. The ANXA3 levels in the patient samples were validated for the prognosis based on age, menopause status, tumor size, tumor node, metastasis stage, the number of lymphatic metastases, oncology grade, and molecular subtyping. An elevated expression of ANXA3 was detected in breast cancer samples, compared to adjacent tissue samples, and significant correlation depending on the number of lymphatic metastases (P=0.001) and histological grade (P=0.004) was observed. The number of lymphatic metastases and ANXA3 expression were identified as independent risk factors affecting the disease-free survival and overall survival. Significantly (P0.05) change in the expression of ANXA3 with respect to age, menopausal status, tumor size, and clinical stage. The findings implicate the expression of ANXA3 with the natural progression of breast cancer and associate it with increased lymphatic metastasis. The study validates the use of ANXA3 as a potential prognosis biomarker for breast cancer.
ISSN:2314-6133
2314-6141
DOI:10.1155/2017/2603685